[237] http://www.dbcg.dk/PDF%20Filer/Kap_1_DBCG_15.06.11.pdf
[238] Møller et al. Acta Oncol 2008; 47:506. http://www.regioner.dk
[239] Paul Kristjansen Kræft – Hvad er det. Nyt Nordisk Forlag 2001
[243] “New studies on surgical options in inherited breast cancer show drastic treatment is not always best.” March 26th, 2010. www.physorg.com
[244] Abstract 7N.Additional source: European Breast Cancer ConferenceSource reference: Heemskerk-Gerritsen BAM, et al “Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?” EBCC 2010; Abstract 500. http://www.breastcancer.org
[245] European Breast Cancer Conference Source reference: Pierce L, et al “Local therapy options in BRCA1/2 carriers with operable breast cancer: the importance of adjuvant chemotherapy” EBCC 2010; http://www.breastcancer.org
[246] Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: A review. J SurgOncol. 2006 Jul 1;94(1):68-80.
[247] HerbermanRB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science. 1981 Oct 2;214(4516):24-30.
[248] MccoyJL, Rucker R, Petros JA. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat. 2000 Apr;60(3):227-34.
[249] Da Costa ML, Redmond P, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. Surgery. 1998 Sep;124(3):516-25.
Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann SurgOncol. 2003 Oct;10(8):972-92.
McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg. 1993 Aug;80(8):1005-7.
Rosenne E, Shakhar G, Melamed R, et al. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun. 2007 May;21(4):395-408.
[250] Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann SurgOncol. 2003 Oct;10(8):972-92.
[251] Ribatti D. History of Research on Tumor Angiogenesis. Springer;2009:9.
Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature’s antiangiogenic therapy. NeuroOncol. 2005 Apr;7(2):106-21.
[252] Baum M, Demicheli R, Hrushesky W, et al. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005 Mar;41(4):508-15.
Folkman J. Fundamental concepts of the angiogenic process. CurrMol Med. 2003 Nov;3(7):643-51.
Pinsolle V, Ravaud A, Baudet J. [Does surgery promote the development of metastasis in melanoma?]. Ann ChirPlastEsthet. 2000 Aug;45(4):485-93.
Raymond E. [Tumor angiogenesis inhibitors: media and scientific aspects]. Presse Med. 1998 Jul 4-11;27(24):1221-4.
[253] Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Dis. 2006-2007;26:99-114.
Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann SurgOncol. 2003 Oct;10(8):972-92.
[254] van der BijGJ, OosterlingSJ, Beelen RH, et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009 May;249(5):727-34.
[255] DowdallJF, Winter DC, Andrews E, et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? J Surg Res. 2002 Sep;107(1):1-6.
[256] Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev. 1987;6(3):433-52.
[257] Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007 Jan 5;282(1):773-81.
[258] Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev. 1987;6(3):433-52.
[259] ten Kate M, HoflandLJ, van GrevensteinWM, et al. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. Int J Cancer. 2004 Dec 20;112(6):943-50.
[260] Asher ME. Surgical considerations in the elderly. J Perianesth Nurs. 2004 Dec;19(6):406–14.
Schmiesing CA, Brodsky JB. The preoperative anesthesia evaluation. Thorac Surg Clin. 2005 May;15(2):305–15.
[261]Patel GK. The role of nutrition in the management of lower extremity wounds. Int J Low Extrem Wounds. 2005a Mar;4(1):12–22.
[262] Lambert SA. The effects of hypnosis/guided imagery on the postoperative course of children. J Dev Behav Pediatr. 1996 Oct;17(5):307–10.
Rapkin DA, Straubing M, et al. Guided imagery, hypnosis and recovery from head and neck cancer surgery: An exploratory study. Int J Clin Exp Hypn. 1991 Oct;39(4):215–26.
[263] Halpin LS, Speir AM, et al. Guided imagery in cardiac surgery. Outcomes Manag. 2002 Jul;6(3):132–7.
Norred CL. Minimizing preoperative anxiety with alternative caring-healing therapies. AORN J. 2000 Nov;72(5): 838–40, 842–3.
[264] Tusek D, Church JM, et al. Guided imagery as a coping strategy for perioperative patients. AORN J. 1997a Oct;66(4):644–9.
Tusek DL, Church JM, et al. Guided imagery: A significant advance in the care of patients undergoing elective colorectal surgery. Dis Colon Rectum. 1997b Feb;40(2):172–8.
[265] Luyten CR, van Overveld FJ, et al. Antioxidant defence during cardiopulmonary bypass surgery. Eur J Cardiothorac Surg. 2005 Apr;27(4):611–6.
Schindler R, Berndt S, et al. Plasma vitamin E and A changes during cardiopulmonary bypass and in the postoperative course. Langenbecks Arch Surg. 2003 Jan;387(9-10):372–8.
[266] Canbaz S, Duran E, et al. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery. Thorac Cardiovasc Surg. 2003 Apr;51(2):57–61.
Xia Z, Gu J, et al. Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1404–10.
[267] DeWeese TL, Hruszkewycz AM, et al. Oxidative stress in chemoprevention trials. Urology. 2001 Apr;57(4 Suppl 1):137–40.
[268] Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 2006 Mar;116(3):598–606.
[269] Potts MB, Koh SE, et al. Traumatic injury to the immature brain: Inflammation, oxidative injury, and iron-mediated damage as potential therapeutic targets. NeuroRx. 2006 Apr;3(2):143–53.
[270] De la Fuente M, Hernanz A, et al. The immune system in the oxidative stress conditions of aging and hypertension: Favorable effects of antioxidants and physical exercise. Antioxid Redox Signal. 2005 Sep;7(9–10):1356–66.
[271] Stark G. Functional consequences of oxidative membrane damage. J Membr Biol. 2005 May;205(1):1–16.
[272] Thurston G, Baluk P, et al. Determinants of endothelial cell phenotype in venules. Microcirculation. 2000 Feb;7(1):67–80.
[273] Fall PJ, Szerlip HM. Lactic acidosis: From sour milk to septic shock. J Intensive Care Med. 2005 Sep;20(5):255–71.
[274] Antall GF, Kresevic D. The use of guided imagery to manage pain in an elderly orthopaedic population. Orthop Nurs. 2004 Sep;23(5):335–40.
Halpin LS, Speir AM, et al. Guided imagery in cardiac surgery. Outcomes Manag. 2002 Jul;6(3):132–7.
Lambert SA. The effects of hypnosis/guided imagery on the postoperative course of children. J Dev Behav Pediatr. 1996 Oct;17(5):307–10.
[275] Khanna S, Roy S, et al. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med. 2001 Jul 1;31(1):38–42.
Khanna S, Venojarvi M, et al. Dermal wound healing properties of redox-active grape seed proanthocyanidins. Free Radic Biol Med. 2002 Oct 15;33(8):1089–96.
[276] Ellis LM, Copeland EM, III, et al. Perioperative nutritional support. Surg Clin North Am. 1991 Jun;71(3):493–507.
[277] Braverman, A.: Medical oncology in the 1990s. Lancet 1991;337:901-902.
[280] http://laegehaandbogen.dk
[281] Alschuler 2007
[282] Forkner, CE: Leukemia and allied disorders. NY: Macmillan 1938.
[283] Pack, GT and Livingstone, EM.: Treatment of cancer and allied diseases, by 147 international authors. NY: Paul B. Hoeber, 1940.
[284] Ward, PS.: American reception of Salvarsan. JHMAS 1981:36.
[285] Stokes, J.:Certain technical requirements in methods of intraveneous injections. Med Rec 1917; 92: 529.
[286] Ehrlich, P.The collected papers of Paul Ehrlich. F. Himmelweit, ed. London: Pergamon, 1956.
Golomb, FM.: Agents used in cancer chemotherapy. Am J surg 1963; 105:579-590.
[287] Patterson, JT.: The dread disease. Cambridge, MA: Harvard University Press, 1987.
[288] Gilman, A.:The initial clinical trial of nitrogen mustard. Am J Surg 1963; 105: 574-578.
[289] Adair, FE and Bagg, HJ.: Experimental and clinical studies on treatment of cancer by dichloroethylsulfide (mustard gas). Ann Surg 1931;93:190.
[290] Perry, MC and Yarbro, JW.: Toxicity of chemotherapy. Orlando: Grune & Stratton, 1984.
[291] Moss, Ralph W. The Cancer Industry. NY: Paragon, 1989
[292] Israel, L.: Conquering cancer. NY: Random House, 1978.
[293] Bross, ID: The NSABP trials (letter). NEJM 1994; 331:809.
[294] Zobrod, CG.: Chemical control of cancer (based on a National Academy of Sciences symposium held in October 1991). PNAS 1972; 69:1042-1046.
[295] Cairns, J.: The treatment of diseases and the war against cancer. Sci Am 1985; 253:51-59.
[296] Greenberg, D.: Progress in cancer research – don´t say it isn´t so. NEJM 1975; 292: 707-708.
[297] Greenberg, D.: Progress in cancer research – don´t say it isn´t so. NEJM 1975; 292: 707-708.
[298] Illich, I.: Medical nemesis: the expropriation of health. NY: bantam Books 1976
[299] Epstein, SS and rennie, SA.: Travesty at wommen´s expense. Los Angeles Times 6/22/92
[300] Bailar, Jc. III and Smith, E.:Progress against cancer? NEJM 1986; 314: 1226-1232.
[301] A Dull Weapon: Chemotherapy Almost Useless in Treating Advanced Organic Cancer—Provocative Theses at the Hamburg Cancer Congress
Artikel i Der Spiegel 33/1990, 174-176 oversat af People Against Cancer, Otho Iowa. Her fra: http://www.mnwelldir.org/docs/fraud/able.htm 2009. Den oprindelige artikel kan læses her: http://www.spiegel.de/spiegel/print/d-13500786.html
[302] Abel, U.: Chemotherapy of advanced epithelial cancer: a critical review. Biomedicine & Pharmacotherapy 1992; 46: 439-452
Abel, U.: Personal communication 5/16/94 (med Ralph Moss). Her i Moss, Ralph W.: Questioning Chemotherapy. Equinox 2004
[303] Abel, Ulrich: Cytostatic Therapy of Advanced Epithelial Tumors — A Critique (Hippocrates Verlag, Stuttgart. 112 pages. 28 marks).
[304] Macaulay, V og Smith, IE.: Advanced Breats Cancer. I: Slevin and Staquet 1986: 273-258.
[305] Shimkin, RJ.:Contrary to Nature (DHEW Publication No. NIH 79-720. Bethesda: NCI, 1979.
[306] Moss, RW.: Big money in new cancer drugs. The Cancer Chronicles 1991: 2: 4-5.
[307] FDA Consumer Memo 73-30, 1973
[308] James, JD et al.: A guide to drug interactions. NY: McGrawHill, 1978.
Kagan, BM et al.: Spotlight on antimicrobial agents. JAMA 1973; 226: 306-310.
[309] Karnofsky, D.: Cancer chemotherapeutic agents. CA Cancer J Clin 1968; 18: 72-79.
[310] Colvin, OM og Chabner, BA. Alkylating agents. I Chabner, BA og Collins, JM (eds). Cancer chemotherapy: principles and practice. Philadelphia: J.B. Lippincott, 1990: 276-313.
[311] Wittnes, RE og Hubbard, S.: Chemotherapy: the properties and uses of single agents. I: Wittnes, 1991: 66-121.
[312] Von Hoff, DD. et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 1979; 91: 710-717.
[313] Moss, Ralph W.: Questioning Chemotherapy. Equinox 2004
[314] Holmes, FA et al.: Phase II trial of taxol: an active drug in metastatic breast cancer. JNCI 1991; 83: 1797-1805.
[315] Rowinsky, EK. et al.: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. JCO 1991; 9: 1704-1712.
[316] Brandwein, MS et al.: Fatal pulmonary lipid embolism associated with taxol therapy. Mt Sinai J Med 1988; 55: 187-189.
[317] J Clin Oncol 1996; 14: 58-65
[318] J Clin Oncol 1999; 17: 2341-54
[319] J Clin Oncol 1999; 17: 2341-54
[320] Moss, Ralph W.: Questioning Chemotherapy. Equinox 2004
[321] http://www.dagensmedicin.dk/nyheder/2006/11/29/intelligente-lagemidler-gor/ 29-11-2006
[322] J Clin Oncol 1999; 17:485. Her i Moss, Ralph W.: Questioning Chemotherapy. Equinox 2004
[323] Clin Oncol (R Coll Radiol) 2004; 16(8): 549-60. http://www.naturli.dk/naturli-viden/behandling/10272-kemoterapi-den-helt-almindelige-gift
[324] http://ing.dk/artikel/720-danskere-udsaettes-arligt-virkningslos-smertelig-kemoterapi-93581
[325] http//:www.naturli/helsenyt/8273-kemoterapi-gavner-kun-hver-10-kvinde/
[326] Sun, Y., Campisi, J., Higano, C., Beer, T.M., Porter, P., Coleman, I., True, L. & Nelson, P.S. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B, Nature Medicine, DOI: 10.1038/nm.2890 http://www.dagensmedicin.dk/videnskab/cancer/kemoterapi-stimulerer-cellevakst-og-gor-krafttumorer-resistente/ Opdateret 22.08.2012 Videnskab: Cancer
http://scienceblog.cancerresearchuk.org/2012/08/06/headlines-about-backfiring-chemotherapy-are-misleading/
[327] Early breast cancer trialist´s collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
[328] Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41:1678-89. http://www.irf.dk/dk/publikationer/rationel_farmakoterapi/maanedsblad/2006/medikamentel_behandling_af_brystkraeft.htm
[329] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1760730/
[330] http://www.breastcancer.org/research-news/ovary-suppression-w-aromasin-better-than-w-tamoxifen
[331] http://www.farma.ku.dk/index.php/Haab-om-bedre-behandling-af-br/1591/0/
[332] Nakagawa, T. et al.: Angiology, vol. 45 s. 333 Maj 1994. Her i: Quillin 2005
[333] Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.
Pavlidis, NA. Et al.: Cancer, vol. 69 s. 2961. 1992. Her i: Quillin 2005
[334] Harris JRMMNL. Malignant tumors of the breast.1997( Section 2).
Cuzick J, Powles T, Veronesi U, Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361(9354):296-300. http://www.irf.dk/dk/publikationer/rationel_farmakoterapi/maanedsblad/2006/medikamentel_behandling_af_brystkraeft.htm
[335] Fornander, T et al.: Effects of tamoxifen on the female genital tract. Ann NY Acad Sci 191; 622: 469-476.
[336] Moss, Ralph W.: Questioning Chemotherapy. Equinox 2004
[337] Veronesi, U., P. Maisonneuve, . Costa, V. Sacchini et al.: Prevention of Breast Cancer with Tamoxifen: preliminary Findings from the Italian randomized Trial among Hysterectomized Women. The Lancet 352 (1998): 93-97
[338] The Lancet 2002; 360: 817-24). http://radiodoktoren.dk/radiodoktoren/2010/11/06/tamoxifen-2
[339] Singer CF, Hudelist G, Schreiber M, Kubista E. Pharmacological modulation of IGF serum concentrations as a therapeutic approach to control the growth of malignant breast tumors. Drugs Today (Barc). 2003 Feb;39(2):115-25.
Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol. 1997 Jan;152(1):39-47.
[340] Publiceret i september nummeret 2012 af PLoS One.
[341] www.skane.se/sv/Webbplatser/Skanes-universitetssjukhus/Nyheter/Arkiv/Nyheter-2013/Sara-har-tagit-ett-steg-narmara-skraddersydd-cancerbehandling/
[342] Cancer 1998; 83:1142-1152.
[343] http://min.medicin.dk/Medicin/Praeparater/1220
[344] Oncology 1998; 12S: 41-4. Her i Moss, Ralph W.: Questioning Chemotherapy. Equinox 2004
[345] http://www.netdoktor.dk
[346] American Association for Cancer Research. “Aromatase inhibitors increase risk of heart disease in postmenopausal women with breast cancer, analysis finds.” ScienceDaily. ScienceDaily, 9 December 2010.
[347] Semin Oncol 1999; 26S: 89-95.
[348] Semin Oncol 1999; 26S: 78-83
[349] Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol (2005) 23: 7811-7819.
[350] Tobias JS. Clinical practice of radiotherapy. Lancet. 1992;339(8786):159-63.
[351] Emami B, Lyman J, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-22.
[352] Burnet NG, Wurm R, et al. Normal tissue radiosensitivity–how important is it? Clin Oncol (R Coll Radiol). 1996;8(1):25-34.
[353] Dunne-Daly CF. Principles of radiotherapy and radiobiology. Semin Oncol Nurs. 1999;15(4):250-9.
[354] Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer. 1999;6(1):41-4.
[355] Kerr JF, Winterford CM, et al. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73(8):2013-26.
[356] Fang YZ, Yang S, et al. Free radicals, antioxidants, and nutrition. Nutrition. 2002;18(10):872-9.
[357] Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol. 2000;32(2):157-70.
[358] Hoskin PJ, Price P, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23(2):74-8.